Compare AEVA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AEVA | FTRE |
|---|---|---|
| Founded | 2019 | 1996 |
| Country | United States | United States |
| Employees | 276 | N/A |
| Industry | Auto Parts:O.E.M. | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 819.5M | 829.3M |
| IPO Year | N/A | 2023 |
| Metric | AEVA | FTRE |
|---|---|---|
| Price | $12.69 | $8.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $26.50 | $15.39 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 05-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | $85.37 | N/A |
| Revenue Next Year | $132.72 | $3.01 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $5.81 | $3.97 |
| 52 Week High | $38.79 | $18.67 |
| Indicator | AEVA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 38.52 |
| Support Level | $12.44 | $8.85 |
| Resistance Level | $17.51 | $11.22 |
| Average True Range (ATR) | 1.33 | 0.64 |
| MACD | -0.26 | 0.13 |
| Stochastic Oscillator | 24.00 | 30.43 |
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.